ReviewFrontiers in bioscience (Scholar edition)2011
RAGE and its ligands in bone metabolism.
Review in Frontiers in bioscience (Scholar edition), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Serum Advanced Glycation End Products as Drivers of Poor Tendon Outcomes in Diabetes? An Emerging Hypothesis and Narrative Review.Endocrinology, diabetes & metabolism · 2026Review
- RAGE-Mediated Signalling in Gynaecological Disorders: Review of Molecular Mechanisms and Therapeutic Perspectives.Expert reviews in molecular medicine · 2026Review
- Macrophage polarization-related genes with potential causal roles in osteoporosis: a multi-omics Mendelian randomization study.Journal of orthopaedic surgery and research · 2026Article
- Engineering bone tissue with mRNA: from molecular design and delivery to clinical applications.Materials today (Kidlington, England) · 2025Article
- Association of plasma levels of protein-bound advanced glycation end-products and their soluble receptors with bone mineral status in young girls with the restrictive type of anorexia nervosa.Archives of osteoporosis · 2025Article
- Correlation Between Blood Glucose Fluctuations and Osteoporosis in Type 2 Diabetes Mellitus.International journal of endocrinology · 2025Review
- Review
- Role of Advanced Glycation End-Products and Oxidative Stress in Type-2-Diabetes-Induced Bone Fragility and Implications on Fracture Risk Stratification.Antioxidants (Basel, Switzerland) · 2023Review
- Parathyroid hormone therapy improves MRSA-infected fracture healing in a murine diabetic model.Frontiers in cellular and infection microbiology · 2023Article
- Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases.Molecules (Basel, Switzerland) · 2022Review
- Development and Regeneration of Muscle, Tendon, and Myotendinous Junctions in Striated Skeletal Muscle.International journal of molecular sciences · 2022Review
- Receptor for Advanced Glycation End Products (RAGE) and Its Polymorphic Variants as Predictive Diagnostic and Prognostic Markers of NSCLCs: a Perspective.Current oncology reports · 2021Review
- Quantitative imaging of the receptor for advanced glycation end-products in prostate cancer.European journal of nuclear medicine and molecular imaging · 2020Article
- Alarmins in Osteoporosis, RAGE, IL-1, and IL-33 Pathways: A Literature Review.Medicina (Kaunas, Lithuania) · 2020Review
- Rps27a might act as a controller of microglia activation in triggering neurodegenerative diseases.PloS one · 2020Article
- Advanced Glycation End Products (AGEs), Receptor for AGEs, Diabetes, and Bone: Review of the Literature.Journal of the Endocrine Society · 2019Review
- High mobility group box 1 protein regulates osteoclastogenesis through direct actions on osteocytes and osteoclasts in vitro.Journal of cellular biochemistry · 2019Article
- Article
- Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma.Antioxidants (Basel, Switzerland) · 2019Article
- RAGE Signaling in Skeletal Biology.Current osteoporosis reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The receptor for advanced glycation end products (RAGE), a member of the immunoglobulin super-family transmembrane proteins, has multiple ligands, thus, is implicated in the pathogenesis of various diseases, including diabetic complications, neurodegenerative disorders, and inflammatory responses. Its function in normal physiology is beginning to be defined, and recent studies have pointed to an important role for RAGE and its ligands (e.g., HMGB1 (high mobility group box 1)) in innate immune response. In addition, RAGE and its ligands are also implicated in osteoclast activation and bone remodeling. Understanding how RAGE and its ligands regulate bone remodeling may provide insight into the pathogenesis of diabetes and chronic inflammation associated bone loss. Recent progress relevant to the functions of RAGE and its ligands in bone remodeling is discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.